ClinicalTrials.Veeva

Menu
S

South Texas Accelerated Research Therapeutics | START Mountain Region

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

SM08502
SL-172154
Abiraterone Acetate
Osimertinib
LP-284
AB801
LP-184
LY3537982
Pembrolizumab
FMC-376

Parent organization

This site is a part of South Texas Accelerated Research Therapeutics

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

28 of 34 total trials

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

This study will evaluate the preliminary efficacy of IMP1734 in patients with recurrent advanced/metastatic breast cancer, ovarian cancer and metasta...

Enrolling
Advanced Solid Tumor
Drug: IMP1734

This is a Phase 1/1b open-label, multi-center dose escalation and dose optimization study, designed to evaluate safety and preliminary efficacy of IA...

Enrolling
HER2 Mutation-Related Tumors
Drug: Trastuzumab
Drug: IAM1363

This is a Phase 1/2, first in human (FIH), open-label, multicenter study of PBI-410 monotherapy and PBI-410 in Combination with Cemiplimab in partici...

Enrolling
Solid Tumor
Drug: PBI-410
Drug: Cemiplimab

The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will...

Enrolling
Solid Tumor, Adult
Unresectable Solid Tumor
Drug: FMC-376

The primary purpose of this study is to assess the safety and tolerability of AB801 in participants with advanced malignancies, and to determine a re...

Enrolling
Advanced Cancer
Drug: Docetaxel
Drug: Zimberelimab

The primary purpose of this study is to assess the safety, tolerability, and pharmacokinetics, and to identify the optimal dose of ADRX-0706 in patie...

Enrolling
Solid Tumors
Drug: ADRX-0706

The aim of this study is to assess the safety and tolerability of BMS-986360 as monotherapy and in combination with chemotherapy or nivolumab in part...

Enrolling
Advanced Solid Tumors
Drug: Capecitabine
Drug: Docetaxel

The purpose of this study is to determine the relative bioavailability (rBA; Period 1) and bioequivalence (BE; Period 2 and 3) of various strengths a...

Active, not recruiting
Prostatic Neoplasms
Drug: Niraparib
Drug: Abiraterone Acetate (AA)
Locations recently updated

The purpose of this study is to determine whether the amount of time before disease progression can be prolonged in participants with metastatic cast...

Enrolling
Inhibitory Checkpoint Molecule
Immunotherapy
Drug: docetaxel
Drug: Prednisone

The purpose of this study is to find out whether the study drug, LY4170156, is safe, tolerable and effective in participants with advanced solid tumo...

Enrolling
Uterine Cervical Neoplasms
Ovarian Neoplasms
Drug: LY4170156

The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of MGC026 in parti...

Enrolling
Small-cell Lung Cancer
Melanoma
Biological: MGC026 Dose for Expansion
Biological: MGC026 Dose Escalation

The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161.

Enrolling
Breast Cancer
Pancreas Cancer
Drug: IDE-161

This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of...

Enrolling
Carcinoma, Non-Small-Cell Lung
Pancreatic Ductal Adenocarcinoma
Drug: PF-08046050

This clinical trial is studying advanced solid tumors. Solid tumors are cancers that start in a part of your body like your lungs or liver instead of...

Enrolling
Other Solid Tumors
Ovarian Neoplasms
Drug: SGN-MesoC2

Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal...

Enrolling
Breast Cancer
Melanoma
Drug: Cemiplimab
Drug: SNS-101 (anti-VISTA)

Genes contain genetic code which tell the body which proteins to make. Some types of cancer are caused by changes, or mutations, in a gene called KRA...

Enrolling
Solid Tumor
Drug: ASP4396

The purpose of this study is to learn about the safety and effects of giving vepdegestrant along with PF-07220060. Vepdegestrant is studied to see if...

Enrolling
Breast Cancer
Drug: vepdegestrant
Drug: PF-07220060

The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, and pharmacokinetics (PK) to determine the maximum tolera...

Enrolling
Solid Tumor
Advanced Ovarian Carcinoma
Drug: NKT3447

This is a phase 1, multi-center, open-label, dose-escalation study of nab-sirolimus in adult patients with locally advanced or metastatic solid tumor...

Enrolling
Advanced Solid Tumor
Tumor
Drug: nab-sirolimus

A phase 1/2 open-label multicenter study will be performed with an initial dose escalation part to determine the MTD and/or the RP2D of MCLA-129 in m...

Enrolling
Non-Small Cell Lung Cancer Metastatic
Gastric Cancer
Drug: MCLA-129
Drug: Osimertinib

Trial sponsors

Seagen logo
B
L
Lilly logo
MacroGenics logo
A
A
Arcus Biosciences logo
Astellas logo
Biohaven logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems